(505) 254-7784 pchelp@pcsanm.org
  • About Us
    • Mission Statement
    • Our Board
    • Organization Description
  • Contact Us
0 Items
Prostate Cancer Support Association of New Mexico
  • Home
  • Start Here
    • Beginner’s Guide
    • Next Steps
  • Meetings
  • Resources
  • Education & Info
    • Helpful Prostate Cancer-Related Websites
    • NM Cancer Resources & Support
    • News You Can Use
    • For Medical Professionals
  • Annual Conference
  • Newsletters
  • Early Detection
    • Early Detection
    • Free PSA Test
Select Page

Decipher Genomic Classifier Shows Prognostic Value in Intermediate-Risk Prostate Cancer

by admin_63069 | Jun 8, 2023 | News You Can Use

Read the latest from Urology Times.

Impact of Endocrine Disrupting Chemicals on Hormone-Sensitive Cancer

by admin_63069 | Jun 5, 2023 | News You Can Use

Two thirds of all cancers are environmentally linked in some way.

Bone Biomarkers Found to be Prognostic for Overall Survival in Prostate Cancer

by admin_63069 | Jun 1, 2023 | News You Can Use

“These results validate the clinical value of bone biomarker assessment in the hormone-sensitive prostate cancer state,” state the authors.

Artificial Intelligence May Enhance Efficacy of Multi-Parametric MRI in Prostate Cancer

by admin_63069 | May 29, 2023 | News You Can Use

Researchers examined the impact of deep learning–based AI software upon radiologists reviewing multiparametric MRI scans in the assessment of clinically significant prostate cancer.

Bisphosphonates May Reduce Fracture Risk in Patients With Metastatic Hormone-Sensitive Prostate Cancer

by admin_63069 | May 25, 2023 | News You Can Use

A database analysis showed that zoledronic acid led to a 64% reduction in fracture risk among patients with metastatic hormone-sensitive prostate cancer.

PSMA-Targeted Therapy May Decrease PSA Levels in Metastatic Prostate Cancer Subset

by admin_63069 | May 22, 2023 | News You Can Use

Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect profiles.
« Older Entries

What’s New

  • Decipher Genomic Classifier Shows Prognostic Value in Intermediate-Risk Prostate Cancer
  • Highlighting Bias and Biological Barriers in Urological Care and Prostate Cancer Research
  • Impact of Endocrine Disrupting Chemicals on Hormone-Sensitive Cancer
  • PMSA PET Offers Patients With Prostate Cancer More Precise Diagnosis
  • Bone Biomarkers Found to be Prognostic for Overall Survival in Prostate Cancer

Disclaimers:

PCSANM provides education, information, and support, not medical advice. Please contact your physician for all your medical concerns. No copyrighted material belonging to others is knowingly used without permission. If any is inadvertently used without permission, please contact our office. Articles are selected from a variety of sources to give as wide a range of content as possible. PCSANM does not endorse or approve, and assumes no responsibility for, the content, accuracy, or completeness of the information presented.

2533 Virginia St. NE, Suite C Albuquerque, NM 87110

Phone: (505) 254-7784
Toll Free: (800) 278-7678
Fax: (505) 254-7786

Email: pchelp@pcsanm.org